GlassScriptPhysician profile
Daniel J Navarro
NPI 1699033092
$3,613.37
in general payments reported to CMS, 2019-2025
34 companies · $1,422 in 2025
The $1,422 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $646 · 2022: $884 · 2023: $177 · 2024: $484 · 2025: $1,422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,083.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.23 | 2021-2023 | |
| Gilead Sciences, INC. | $386.75 | 2023-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $246.96 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $240.12 | 2025 | Rexulti |
| Edwards Lifesciences Corporation | $211.43 | 2024 | Sapien 3 Ultra Resilia |
| Neurocrine Biosciences, INC. | $174.92 | 2025 | |
| Cvrx, INC. | $147.20 | 2024 | Barostim Neo System |
| Biohaven Pharmaceuticals, INC. | $145.81 | 2021 | |
| Abbott Laboratories | $138.21 | 2021-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $135.42 | 2025 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $125.99 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $122.55 | 2025 | Fanapt |
| Kyowa Kirin, INC. | $121.83 | 2025 | |
| Viiv Healthcare Company | $119.85 | 2025 | Apretude |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $105.55 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $103.08 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.09 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $64.80 | 2022 | |
| Lundbeck LLC | $63.77 | 2022 | |
| Tanabe Pharma America, INC. | $61.17 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.48 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $40.98 | 2021 | |
| Avanir Pharmaceuticals, INC. | $37.55 | 2022 | |
| Genzyme Corporation | $33.64 | 2022 | |
| Sk Life Science, INC. | $29.62 | 2021 | |
| Impel Pharmaceuticals INC. | $24.53 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.63 | 2022 | |
| Csl Behring | $22.08 | 2022 | |
| Lucid Diagnostics INC. | $18.08 | 2022 | |
| Dexcom, INC. | $17.34 | 2022 | |
| Acorda Therapeutics, INC | $16.97 | 2022 | |
| Pfizer INC. | $14.75 | 2023 | |
| Exact Sciences Corporation | $13.32 | 2023 | Cologuard Collection Kit |
| Lilly USA, LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.